![Jakob Dupont](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jakob Dupont
Director/Board Member at
BOLT BIOTHERAPEUTICS, INC.
Net worth: 119 163 $ as of 2026-06-29
Profile
Jakob Dupont is currently Independent Non-Executive Director at Imugene Ltd. since 2022, Director at Avenzo Therapeutics, Inc. since 2024, Independent Director at Pyxis Oncology, Inc. since 2023, Director at Bolt Biotherapeutics, Inc. since 2024, Executive Partner at Sofinnova Investments, Inc. since 2023, and Advisor at Ambrx, Inc. since 2021.
Former roles include Global Director-Medical at Genentech, Inc. from 2006 to 2011, Director at Apexigen America, Inc. from 2020 to 2023, Independent Director at Apexigen, Inc. from 2020 to 2023, VP & Global Head-Gynecologic Cancer Development at Genentech, Inc. from 2017 to 2018, Faculty Member at Memorial Sloan Kettering Cancer Center, Chief Medical Officer & Senior Vice President at Mereo BioPharma 5, Inc. from 2012 to 2016, EVP, Global Head-Research & Development at Atara Biotherapeutics, Inc. from 2020 to 2023, and Chief Medical Officer at Gossamer Bio, Inc. from 2018 to 2020.
Education includes graduate degree from New York University in 1991, undergraduate degree from Vassar College in 1987, and doctorate from Weill Cornell Medical College in 1996.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PYXIS ONCOLOGY, INC. 0.06% | 2026-06-29 | 38,741 ( 0.06% ) | 116 610 $ | 2026-06-29 |
IMUGENE LTD 0.01% | 2025-12-16 | 32,038 ( 0.01% ) | 2 552 $ | 2026-06-29 |
| 2026-06-09 | 0 ( -.--% ) | - $ | 2026-06-29 |
Jakob Dupont active positions
| Companies | Position | Start |
|---|---|---|
| IMUGENE LIMITED | Director/Board Member | 2022-09-06 |
| AMBRX INC | Consultant / Advisor | 2021-02-28 |
| PYXIS ONCOLOGY, INC. | Director/Board Member | 2023-08-22 |
| BOLT BIOTHERAPEUTICS, INC. | Director/Board Member | 2024-09-02 |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Private Equity Investor | 2023-04-30 |
Avenzo Therapeutics, Inc.
 Avenzo Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development for oncology therapies used in treating of cancer | Director/Board Member | 2024-02-29 |
Former positions of Jakob Dupont
| Companies | Position | End |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2023-11-30 |
| APEXIGEN, INC. | Director/Board Member | 2023-08-22 |
Apexigen America, Inc.
 Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology | Director/Board Member | 2023-07-31 |
| ░░░░░░░░ ░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Jakob Dupont
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
97
1st degree connections
16
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 16 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Mereo BioPharma 5, Inc.
 Mereo BioPharma 5, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-cancer stem cell therapeutics | Health Technology |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment invests in companies located in the United States and Europe. The firm targets companies operating in the fields of health technology services and life science. It participates in early and later stage capital requirements. | Finance |
Imugene Ltd.
 Imugene Ltd. BiotechnologyHealth Technology Operates as a a clinical stage immuno-oncology company | Health Technology |
New York University
 New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vassar College
 Vassar College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambrx, Inc.
 Ambrx, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Operates cancer hospital | Health Services |
Weill Cornell Medical College
 Weill Cornell Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Apexigen America, Inc.
Apexigen America, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology | Health Technology |
Atara Biotherapeutics, Inc.
 Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Bolt Biotherapeutics, Inc.
 Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Gossamer Bio, Inc.
 Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Pyxis Oncology, Inc.
 Pyxis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a preclinical oncology company focused on developing an arsenal of next-generation therapeutics | Health Technology |
Apexigen, Inc.
 Apexigen, Inc. BiotechnologyHealth Technology Develops antibody therapeutics for the treatment of cancer | Health Technology |
Avenzo Therapeutics, Inc.
Avenzo Therapeutics, Inc. BiotechnologyHealth Technology Engages in research and development for oncology therapies used in treating of cancer | Health Technology |
- Stock Market
- Insiders
- Jakob Dupont
